SS-31 Elamipretide Peptide: Research Guide and Where to Buy

What Is SS-31 (Elamipretide)?

SS-31 (elamipretide) is a mitochondria-targeting tetrapeptide developed by Stealth BioTherapeutics that selectively concentrates in the inner mitochondrial membrane. Its sequence — D-Arg-Dmt-Lys-Phe-NH2 — includes a dimethyltyrosine residue that confers high affinity for cardiolipin, the signature phospholipid of the inner mitochondrial membrane and a critical structural component of the electron transport chain (ETC).

Monthly search interest in “SS-31 for sale” and related terms has risen sharply since 2023, reflecting growing research demand in aging, cardiovascular, and neurodegenerative disease study. As mitochondrial dysfunction has moved to the center of geroscience research, SS-31 has become one of the most-cited mitochondrial-targeted peptides in the published literature.

Mechanism of Action

SS-31 exerts its effects through direct interaction with cardiolipin in the inner mitochondrial membrane:

• Cardiolipin Stabilization: Binds cardiolipin and prevents its oxidation by cytochrome c, preserving membrane structure
• ETC Complex I–IV Optimization: Restores electron transfer efficiency across complexes I, III, and IV
• ROS Suppression: Reduces mitochondrial reactive oxygen species production at the source
• ATP Production: Increases ATP synthesis by improving proton gradient maintenance
• Cristae Architecture: Preserves inner membrane cristae structure essential for energy coupling
• Mitochondrial Dynamics: Supports balanced fusion and fission by preventing cardiolipin redistribution

Unlike antioxidants that act downstream after ROS are produced, SS-31 targets the origin point of mitochondrial oxidative stress, making it particularly valuable for research into chronic mitochondrial dysfunction states.

Preclinical and Clinical Research Data

Cardiac Research

SS-31 has generated compelling data in cardiac ischemia-reperfusion (I/R) injury models:

• Multiple rodent studies demonstrate 40–60% reduction in infarct size when administered before or at reperfusion
• Preserved left ventricular function and reduced cardiomyocyte apoptosis in I/R models
• Phase 2 EMBRACE-STEMI trial (2015) showed trends toward improved microvascular function in STEMI patients, though primary endpoint was not met
• Phase 2 PROGRESS-HF trial investigated SS-31 (elamipretide) in HFrEF (heart failure with reduced ejection fraction), showing improvements in exercise tolerance and quality of life markers

Aging and Skeletal Muscle

A landmark 2021 Nature Aging study demonstrated that systemic SS-31 administration in aged mice:

• Reversed age-related declines in mitochondrial ATP production in skeletal muscle
• Improved muscle fiber morphology and contractile function
• Reduced markers of mitochondrial oxidative stress and inflammation
• These effects persisted beyond the treatment period, suggesting durable mechanistic changes

Renal Research

SS-31 has also been investigated in acute kidney injury (AKI) models:

• Reduced renal tubular cell apoptosis in cisplatin-induced AKI models
• Improved glomerular filtration rate markers and renal mitochondrial membrane potential
• Attenuated inflammatory cytokine production in ischemic renal injury models

Neurodegeneration Models

• Reduced amyloid-β-induced mitochondrial dysfunction in Alzheimer’s cell models
• Preserved dopaminergic neuron mitochondrial function in MPTP-induced Parkinson’s models
• Improved cognitive performance markers in aged rodent models

Dosage Reference for Research

Research Context	Typical Dose	Route	Notes
In vitro (cell culture)	10 nM – 1 µM	Media addition	Concentration-dependent effects
Rodent (acute)	1–5 mg/kg	SC or IV	I/R injury, pre-treatment
Rodent (chronic aging)	3 mg/kg/day	SC pump	Continuous infusion in longevity studies
Clinical trials (PROGRESS-HF)	40 mg/day	SC injection	28-week protocol

For research reference only. Not dosing guidance for human use.

SS-31 vs. MitoQ — Research Comparison

Parameter	SS-31 (Elamipretide)	MitoQ
Mechanism	Cardiolipin binding, ETC stabilization	Ubiquinone delivery to mitochondria
Target site	Inner mitochondrial membrane (IMM)	IMM via TPP+ cation
ROS suppression	Upstream (prevents production)	Downstream (scavenges produced ROS)
Clinical data	Phase 2 cardiac trials completed	Human supplementation studies
Research format	Peptide, injectable	Small molecule, oral

Safety and Tolerability

SS-31 has demonstrated a favorable safety profile across preclinical species and in Phase 2 human trials:

• No significant organ toxicity at therapeutic doses in rodent and primate studies
• Most common adverse events in human trials: mild injection site reactions
• No dose-limiting toxicity observed in completed Phase 2 programs
• Peptide does not cross the blood-brain barrier in significant quantities (relevant for CNS research design)

Where to Buy SS-31 for Research

When sourcing SS-31 for laboratory use, quality criteria to prioritize:

• HPLC purity ≥99% with certificate of analysis
• Mass spectrometry (LCMS) identity confirmation per batch
• Sterility testing and endotoxin documentation
• Lyophilized format for long-term stability at −20°C

Research Disclaimer: All information on this page is for educational and scientific reference purposes only. SS-31 is not approved for human use. This product is sold strictly for in vitro research and laboratory use only. Not for human consumption. Researchers must comply with all applicable local regulations.